Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 7/20 | 1.00 |
| ▸ | MGLL | Q99685 | 6/20 | 0.68 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785894 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43882 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL1574552 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43969 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779453 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL24939859 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6934781 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL3291535 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6940132 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779402 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4253958-A | — | — | None | — | — | JP | disclosed |
| JP-4308567-A | — | — | None | — | — | JP | disclosed |
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. | 2021-12-28 | — | — | US | disclosed |
| CN-112142855-A | Protein for diabetes treatment, protein conjugate and application thereof | 爱德迪安（北京）生物技术有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-10472404-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. (CN) | 2019-11-12 | — | — | US | disclosed |
| EP-2851429-B1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | ADDA BIOTECH INC (CN) | 2019-07-24 | — | — | EP | disclosed |
| CN-107739409-A | Albumen, protein conjugate and its application for treating diabetes | 爱德迪安（北京）生物技术有限公司 | 2018-02-27 | — | — | CN | disclosed |
| CN-104302772-B | Protein for diabetes treatment, protein conjugate and application thereof | 爱德迪安（北京）生物技术有限公司 | 2017-11-10 | — | — | CN | disclosed |
| US-9745359-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20170233447-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | ADDA BIOTECH INC. (CN) | 2017-08-17 | — | — | US | disclosed |
| US-20150183847-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | ADDA BIOTECH INC. (CN) | 2015-07-02 | — | — | US | disclosed |
| EP-2851429-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | Adda Biotech Inc. (CN) | 2015-03-25 | — | — | EP | disclosed |
| EP-0507348-B1 | Superoxide dismutase derivatives | KURARAY CO (JP) | 1997-07-09 | — | — | EP | disclosed |
| US-5360914-A | Intermediates for superoxide dismutase derivatives | KURARAY CO., LTD. (JP) | 1994-11-01 | — | — | US | disclosed |
| US-5238837-A | Antiinflammatory agents, antiulcer agents | KURARAY CO., LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| JP-H04308567-A | LONG CHAIN CARBOXYLIC ACID MALEIMIDE | KURARAY CO LTD | 1992-10-30 | — | — | JP | disclosed |
| EP-0507348-A2 | Superoxide dismutase derivatives | KURARAY CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| JP-H04253958-A | LONG-CHAIN CARBOXYLIC ACID MALEIMIDE | KURARAY CO LTD | 1992-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | GLP1R, GIPR, IAPP | PTGS1 2008/4885PTGS2 3490/4885MGLL 2213/4885 |
| US-10472404-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | GLP1R, GIPR, IAPP | PTGS1 2008/4885PTGS2 3490/4885MGLL 2213/4885 |
| US-20150183847-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | GLP1R, GIPR, IAPP | PTGS1 1846/4885PTGS2 3363/4885MGLL 2047/4885 |
| US-20170233447-A1 | PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF | GLP1R, GIPR, IAPP | PTGS1 2008/4885PTGS2 3490/4885MGLL 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.